SRPIN340 5 mg | Purity Not Available
TargetMol
SRPIN340, a serine/arginine-rich protein kinase (SRPK)-specific inhibitor, is potent for SRPK1 (IC50 = 0.89 uM).
More Information Supplier PageSRPIN340
Search Results
Rac-Belinostat 10 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat
Rac-Belinostat 100 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat
ZLN005 50 mg | Purity Not Available
TargetMol
ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005
ZLN005 10 mg | Purity Not Available
TargetMol
ZLN005 is an effective and tissue-specific transcriptional activator of PGC-1α.
More Information Supplier PageZLN005
MBX-2982 5 mg | 98.83%
TargetMol
MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier PageMBX-2982
MBX-2982 50 mg | 98.83%
TargetMol
MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier PageMBX-2982
MBX-2982 25 mg | 98.83%
TargetMol
MBX-2982 is a selective, orally-available GPR119 agonist, used for the treatment of diabetes.
More Information Supplier PageMBX-2982
Rac-Belinostat 200 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat
Rac-Belinostat 25 mg | 99.93%
TargetMol
Rac-Belinostat (PX-105684) is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
More Information Supplier PageRac-Belinostat